Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved..
Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide. Currently, it is well established that dyslipidemia is one of the major risk factors leading to the development of atherosclerosis and CVD. Statins remain the standard-of-care in the treatment of hypercholesterolemia and their use has significantly reduced cardiovascular morbidity and mortality. In addition, recent advances in lipid-modifying therapies, such as the development of proprotein convertase subtilisin/kexin type 9 inhibitors, have further improved cardiovascular outcomes in patients with hypercholesterolemia. However, despite significant progress in the treatment of dyslipidemia, there is still considerable residual risk of recurring cardiovascular events. Furthermore, in some cases, an effective therapy for the identified primary cause of a specific dyslipidemia has not been found up to date. Thus, a number of novel pharmacological interventions are under early human trials, targeting different molecular pathways of lipid formation, regulation and metabolism. This editorial aims to discuss the current clinical and scientific data on new promising lipid-modifying therapies addressing unmet needs in CVD, which may prove beneficial in the near future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
World journal of cardiology - 11(2019), 11 vom: 26. Nov., Seite 256-265 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kosmas, Constantine E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular disease |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4330/wjc.v11.i11.256 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304005886 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304005886 | ||
| 003 | DE-627 | ||
| 005 | 20231225114038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4330/wjc.v11.i11.256 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1013.xml |
| 035 | |a (DE-627)NLM304005886 | ||
| 035 | |a (NLM)31798792 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kosmas, Constantine E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide. Currently, it is well established that dyslipidemia is one of the major risk factors leading to the development of atherosclerosis and CVD. Statins remain the standard-of-care in the treatment of hypercholesterolemia and their use has significantly reduced cardiovascular morbidity and mortality. In addition, recent advances in lipid-modifying therapies, such as the development of proprotein convertase subtilisin/kexin type 9 inhibitors, have further improved cardiovascular outcomes in patients with hypercholesterolemia. However, despite significant progress in the treatment of dyslipidemia, there is still considerable residual risk of recurring cardiovascular events. Furthermore, in some cases, an effective therapy for the identified primary cause of a specific dyslipidemia has not been found up to date. Thus, a number of novel pharmacological interventions are under early human trials, targeting different molecular pathways of lipid formation, regulation and metabolism. This editorial aims to discuss the current clinical and scientific data on new promising lipid-modifying therapies addressing unmet needs in CVD, which may prove beneficial in the near future | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Dyslipidemia | |
| 650 | 4 | |a Lipid-modifying therapies | |
| 700 | 1 | |a Sourlas, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Silverio, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Montan, Peter D |e verfasserin |4 aut | |
| 700 | 1 | |a Guzman, Eliscer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of cardiology |d 2009 |g 11(2019), 11 vom: 26. Nov., Seite 256-265 |w (DE-627)NLM201987775 |x 1949-8462 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:11 |g day:26 |g month:11 |g pages:256-265 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4330/wjc.v11.i11.256 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 11 |b 26 |c 11 |h 256-265 | ||